P/B
0,4
Eocene
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
2013
(13 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
Israel
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
15,9
EPS
—
Market Cap
Market Cap
4,9M
EV
-6,2M
EV/Revenue
0
EV/EBITDA
0,6
EV/EBIT
0,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-50,2%
Total Yield
-50,2%
Payout
0%
Retained Earnings
-215,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,9%
% Goodwill
9,6%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-22,4%
CAGR Net Income 5Y
-17,3%
CAGR EPS 5Y
-63%
CAGR OCF 5Y
-22,4%
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
4,2
Quick Ratio
4,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!